Intellia Thera CS (NTLA)

$11.60 -0.49 (-4.05%)
Market Cap 1.69B
Revenue (ttm) 67.67M
Net Income (ttm) -412.69M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -609.86%
Debt to Equity Ratio 0.00
Volume 3,178,300
Avg Vol 4,916,200
Day's Range N/A - N/A
Shares Out 140.13M
Stochastic %K 57%
Beta 1.81
Analysts Sell
Price Target $23.47

Company Profile

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-20...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 285 6200
Address:
40 Erie Street, Suite 130, Cambridge, United States
BillyBlanks77
BillyBlanks77 Aug. 19 at 12:18 PM
$NTLA Does anyone have the most recent data on how much is left in their shelf registration? Once they are done selling or even close to done, this stock is going to absolutely rip.
0 · Reply
tiddyy
tiddyy Aug. 19 at 12:03 PM
$NTLA Baker Bros know where the real money is, if you guys did some research they exited when Nex-Z was paused in October 2025, you can see their filings position was closed in Q3 2025 They reopened their position again once Nex-Z have got clearance to continue the trial now The BLA submission is cool and all, but what is severely being undervalued is that Nex-Z asset The enrollment continuing for Nex-Z + the profit taking from the Phase 3 data from Lonvo-Z + healthy cash balance + the BLA submission makes me think you getting a very nice discount at $12 per share
0 · Reply
tiddyy
tiddyy Aug. 19 at 9:00 AM
$NTLA Starting position
0 · Reply
Victor3392
Victor3392 Aug. 18 at 9:46 PM
$NTLA There is a time in bio to buy and its just before an FDA BLA approval for the first CRISPR in history to be approved !!
0 · Reply
Victor3392
Victor3392 Aug. 18 at 8:43 PM
$NTLA Shorts are desperate! LoL Sitting with 25000 shares and feel comfort!
0 · Reply
Gladiator007
Gladiator007 Aug. 18 at 7:00 PM
$NTLA Completly derisked, BLA filing underway, cash runway into 2028 and you think single digits coming? LMAO
1 · Reply
accretivewealth
accretivewealth Aug. 18 at 6:52 PM
$NTLA hate to think it, but it could go to single digits again on momentum and forced selling alone, regardless of fundamentals. Looking at some tax harvesting, maybe get back in at a later date (+31 days).
4 · Reply
accretivewealth
accretivewealth Aug. 18 at 5:09 PM
$NTLA stock acts like death, ugh!
0 · Reply
0x126
0x126 Aug. 18 at 3:01 PM
$NTLA no news? Price is just games
1 · Reply
SternInvesting10
SternInvesting10 Aug. 18 at 3:00 PM
$CRSP $NTLA Weak and pathetic Cathie Wood scams. She got it wrong but can’t admit it. So double down and lose your investors hundreds of millions in losses and billions in opportunity costs.
2 · Reply
Latest News on NTLA
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 7, 2026, 4:01 PM EDT - 11 days ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NTLA

Intellia Therapeutics upgraded to Outperform from In Line at Evercore ISI

2026-08-07T11:56:04.000Z - 12 days ago

Intellia Therapeutics upgraded to Outperform from In Line at Evercore ISI

NTLA

Intellia Therapeutics upgraded to Outperform from In Line at Evercore ISI

2026-08-07T11:50:20.000Z - 12 days ago

Intellia Therapeutics upgraded to Outperform from In Line at Evercore ISI

NTLA

Intellia Therapeutics Earnings Call Transcript: Q2 2026

Aug 6, 2026, 8:00 AM EDT - 13 days ago

Intellia Therapeutics Earnings Call Transcript: Q2 2026

Intellia Therapeutics Earnings release: Q2 2026

Aug 6, 2026, 8:00 AM EDT - 13 days ago

Intellia Therapeutics Earnings release: Q2 2026

Intellia Therapeutics Quarterly report: Q2 2026

Aug 6, 2026, 8:00 AM EDT - 13 days ago

Intellia Therapeutics Quarterly report: Q2 2026

Intellia Therapeutics reports Q2 EPS (80c), consensus (78c)

2026-08-06T11:40:45.000Z - 13 days ago

Intellia Therapeutics reports Q2 EPS (80c), consensus (78c)

NTLA

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Aug 6, 2026, 7:00 AM EDT - 13 days ago

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

NTLA

Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates

Jul 30, 2026, 8:00 AM EDT - 20 days ago

Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates

NTLA

Intellia Therapeutics downgraded to Underperform from Peer Perform at Wolfe Research

2026-07-15T21:20:17.000Z - 4 weeks ago

Intellia Therapeutics downgraded to Underperform from Peer Perform at Wolfe Research

NTLA

Intellia Therapeutics price target raised to $17 from $12 at Wedbush

2026-07-10T12:06:00.000Z - 5 weeks ago

Intellia Therapeutics price target raised to $17 from $12 at Wedbush

ALNY AZN IONS NTLA

Intellia Therapeutics rises 12.9%

2026-06-17T16:06:29.000Z - 2 months ago

Intellia Therapeutics rises 12.9%

NTLA

Intellia Therapeutics rises 10.7%

2026-06-17T14:07:55.000Z - 2 months ago

Intellia Therapeutics rises 10.7%

NTLA

Intellia Therapeutics presents additional results from Phase 3 HAELO trial

2026-06-14T20:35:58.000Z - 2 months ago

Intellia Therapeutics presents additional results from Phase 3 HAELO trial

NTLA

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Jun 13, 2026, 7:30 AM EDT - 2 months ago

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

NTLA

Intellia Therapeutics Transcript: AGM 2026

Jun 9, 2026, 9:00 AM EDT - 2 months ago

Intellia Therapeutics Transcript: AGM 2026

Intellia Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 4:55 PM EDT - 2 months ago

Intellia Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

Jun 1, 2026, 7:30 AM EDT - 2 months ago

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

NTLA

Intellia Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 20, 2026, 2:35 PM EDT - 3 months ago

Intellia Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

Intellia Therapeutics price target raised to $17 from $13 at Bernstein

2026-05-13T10:34:18.000Z - 3 months ago

Intellia Therapeutics price target raised to $17 from $13 at Bernstein

NTLA

Intellia Therapeutics price target lowered to $25 from $30 at H.C. Wainwright

2026-05-13T10:28:35.000Z - 3 months ago

Intellia Therapeutics price target lowered to $25 from $30 at H.C. Wainwright

NTLA

Intellia Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 6:40 PM EDT - 3 months ago

Intellia Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

Intellia Therapeutics price target lowered to $19 from $20 at BofA

2026-05-12T16:07:18.000Z - 3 months ago

Intellia Therapeutics price target lowered to $19 from $20 at BofA

NTLA

Intellia Therapeutics price target lowered to $49 from $58 at Canaccord

2026-05-12T11:12:55.000Z - 3 months ago

Intellia Therapeutics price target lowered to $49 from $58 at Canaccord

NTLA

Intellia Therapeutics reports Q1 EPS (81c), consensus (90c)

2026-05-11T17:26:11.000Z - 3 months ago

Intellia Therapeutics reports Q1 EPS (81c), consensus (90c)

NTLA

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

May 11, 2026, 7:30 AM EDT - 3 months ago

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

NTLA

Intellia Therapeutics Earnings release: Q1 2026

May 11, 2026, 7:30 AM EDT - 3 months ago

Intellia Therapeutics Earnings release: Q1 2026

Intellia Therapeutics Quarterly report: Q1 2026

May 11, 2026, 7:30 AM EDT - 3 months ago

Intellia Therapeutics Quarterly report: Q1 2026

Intellia Therapeutics to Participate in Upcoming Investor Conferences

May 5, 2026, 7:30 AM EDT - 3 months ago

Intellia Therapeutics to Participate in Upcoming Investor Conferences

NTLA

Cathie Wood’s ARK Investment buys 141K shares of Intellia Therapeutics today

2026-05-02T00:11:02.000Z - 3 months ago

Cathie Wood’s ARK Investment buys 141K shares of Intellia Therapeutics today

NTLA

Intellia Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Intellia Therapeutics Proxy statement: Proxy filing

Intellia Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Intellia Therapeutics Proxy statement: Proxy filing

Cathie Wood’s ARK Investment buys 2.4M shares of Intellia Therapeutics today

2026-04-30T03:26:02.000Z - 3 months ago

Cathie Wood’s ARK Investment buys 2.4M shares of Intellia Therapeutics today

NTLA

Intellia Therapeutics 16.7M share Secondary priced at $10.75

2026-04-29T15:02:56.000Z - 3 months ago

Intellia Therapeutics 16.7M share Secondary priced at $10.75

NTLA

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

Apr 29, 2026, 7:00 AM EDT - 4 months ago

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

NTLA

Cathie Wood’s ARK Investment buys 596K shares of Intellia Therapeutics today

2026-04-29T00:13:03.000Z - 4 months ago

Cathie Wood’s ARK Investment buys 596K shares of Intellia Therapeutics today

NTLA

Intellia Announces Proposed Public Offering of Common Stock

Apr 27, 2026, 4:01 PM EDT - 4 months ago

Intellia Announces Proposed Public Offering of Common Stock

NTLA

Intellia Therapeutics Transcript: Study result

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Intellia Therapeutics Transcript: Study result

Intellia Therapeutics Press release: Study result

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Intellia Therapeutics Press release: Study result

Intellia Therapeutics Slides: Study result

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Intellia Therapeutics Slides: Study result

Intellia Therapeutics' rare genetic disorder therapy meets main goal in trial

Apr 27, 2026, 7:06 AM EDT - 4 months ago

Intellia Therapeutics' rare genetic disorder therapy meets main goal in trial

NTLA

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial

Apr 27, 2026, 7:01 AM EDT - 4 months ago

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial

NTLA

Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema

Apr 27, 2026, 7:00 AM EDT - 4 months ago

Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema

NTLA

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

Apr 27, 2026, 7:00 AM EDT - 4 months ago

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

NTLA

Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026

Apr 24, 2026, 4:05 PM EDT - 4 months ago

Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026

NTLA

Intellia Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 8:40 AM EDT - 5 months ago

Intellia Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Intellia Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 1:10 PM EST - 6 months ago

Intellia Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026

Mar 3, 2026, 7:30 AM EST - 6 months ago

Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026

NTLA

US FDA lifts clinical hold on Intellia's heart disease gene therapy trial

Mar 2, 2026, 7:40 AM EST - 6 months ago

US FDA lifts clinical hold on Intellia's heart disease gene therapy trial

NTLA

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM

Mar 2, 2026, 7:30 AM EST - 6 months ago

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM

NTLA

Intellia Therapeutics Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:00 AM EST - 6 months ago

Intellia Therapeutics Earnings Call Transcript: Q4 2025

Intellia Therapeutics Annual report: Q4 2025

Feb 26, 2026, 8:00 AM EST - 6 months ago

Intellia Therapeutics Annual report: Q4 2025

Intellia Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 8:00 AM EST - 6 months ago

Intellia Therapeutics Earnings release: Q4 2025

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Feb 26, 2026, 7:30 AM EST - 6 months ago

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

NTLA

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Feb 19, 2026, 7:30 AM EST - 6 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

NTLA

US FDA lifts clinical hold on Intellia's nerve disease trail

Jan 27, 2026, 8:13 AM EST - 7 months ago

US FDA lifts clinical hold on Intellia's nerve disease trail

NTLA

Intellia Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 12:00 PM EST - 7 months ago

Intellia Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Intellia Therapeutics Slides: Corporate presentation

Jan 8, 2026, 7:00 AM EST - 7 months ago

Intellia Therapeutics Slides: Corporate presentation

Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 7:30 AM EST - 8 months ago

Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

NTLA

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Nov 10, 2025, 3:17 PM EST - 10 months ago

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

NTLA

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Nov 8, 2025, 5:13 PM EST - 10 months ago

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

NTLA

Intellia Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 9:30 AM EST - 10 months ago

Intellia Therapeutics Quarterly report: Q3 2025

Intellia Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 9:30 AM EST - 10 months ago

Intellia Therapeutics Earnings release: Q3 2025

US FDA places clinical hold on Intellia's two gene-editing treatment trials

Oct 29, 2025, 5:11 PM EDT - 10 months ago

US FDA places clinical hold on Intellia's two gene-editing treatment trials

NTLA

Intellia Therapeutics Transcript: Study Update

Oct 27, 2025, 8:30 AM EDT - 10 months ago

Intellia Therapeutics Transcript: Study Update

Intellia Therapeutics Press release: Study Update

Oct 27, 2025, 8:30 AM EDT - 10 months ago

Intellia Therapeutics Press release: Study Update

Intellia pauses late-stage trials of gene-editing treatment after serious liver event

Oct 27, 2025, 7:38 AM EDT - 10 months ago

Intellia pauses late-stage trials of gene-editing treatment after serious liver event

NTLA

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

Oct 27, 2025, 7:30 AM EDT - 10 months ago

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

NTLA

Intellia Therapeutics Slides: Company Presentation

Sep 30, 2025, 7:00 AM EDT - 11 months ago

Intellia Therapeutics Slides: Company Presentation

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Sep 25, 2025, 9:52 AM EDT - 11 months ago

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

NTLA

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

Sep 18, 2025, 7:30 AM EDT - 11 months ago

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

NTLA

Why big players are pouring millions in THIS biotech stock

Sep 1, 2025, 8:43 AM EDT - 1 year ago

Why big players are pouring millions in THIS biotech stock

NTLA

Intellia Therapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Earnings Call Transcript: Q2 2025

Intellia Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Quarterly report: Q2 2025

Intellia Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Earnings release: Q2 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aug 1, 2025, 7:30 AM EDT - 1 year ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NTLA

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

Jul 31, 2025, 7:30 AM EDT - 1 year ago

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

NTLA

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Jun 15, 2025, 10:45 AM EDT - 1 year ago

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

NTLA

Intellia Therapeutics Transcript: AGM 2025

Jun 11, 2025, 9:00 AM EDT - 1 year ago

Intellia Therapeutics Transcript: AGM 2025

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

May 18, 2025, 7:25 AM EDT - 1 year ago

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

NTLA

Intellia Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 13, 2025, 7:20 PM EDT - 1 year ago

Intellia Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

Intellia Therapeutics Earnings Call Transcript: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Earnings Call Transcript: Q1 2025

Intellia Therapeutics Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Quarterly report: Q1 2025

Intellia Therapeutics Earnings release: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Earnings release: Q1 2025

Intellia Therapeutics Slides: Corporate Presentation

May 7, 2025, 7:00 AM EDT - 1 year ago

Intellia Therapeutics Slides: Corporate Presentation

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

May 1, 2025, 7:30 AM EDT - 1 year ago

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

NTLA

Intellia Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Proxy statement: Proxy Filing

Intellia Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Proxy statement: Proxy Filing

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Apr 23, 2025, 9:50 AM EDT - 1 year ago

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

NTLA

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

Apr 14, 2025, 10:58 AM EDT - 1 year ago

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

NTLA

BillyBlanks77
BillyBlanks77 Aug. 19 at 12:18 PM
$NTLA Does anyone have the most recent data on how much is left in their shelf registration? Once they are done selling or even close to done, this stock is going to absolutely rip.
0 · Reply
tiddyy
tiddyy Aug. 19 at 12:03 PM
$NTLA Baker Bros know where the real money is, if you guys did some research they exited when Nex-Z was paused in October 2025, you can see their filings position was closed in Q3 2025 They reopened their position again once Nex-Z have got clearance to continue the trial now The BLA submission is cool and all, but what is severely being undervalued is that Nex-Z asset The enrollment continuing for Nex-Z + the profit taking from the Phase 3 data from Lonvo-Z + healthy cash balance + the BLA submission makes me think you getting a very nice discount at $12 per share
0 · Reply
tiddyy
tiddyy Aug. 19 at 9:00 AM
$NTLA Starting position
0 · Reply
Victor3392
Victor3392 Aug. 18 at 9:46 PM
$NTLA There is a time in bio to buy and its just before an FDA BLA approval for the first CRISPR in history to be approved !!
0 · Reply
Victor3392
Victor3392 Aug. 18 at 8:43 PM
$NTLA Shorts are desperate! LoL Sitting with 25000 shares and feel comfort!
0 · Reply
Gladiator007
Gladiator007 Aug. 18 at 7:00 PM
$NTLA Completly derisked, BLA filing underway, cash runway into 2028 and you think single digits coming? LMAO
1 · Reply
accretivewealth
accretivewealth Aug. 18 at 6:52 PM
$NTLA hate to think it, but it could go to single digits again on momentum and forced selling alone, regardless of fundamentals. Looking at some tax harvesting, maybe get back in at a later date (+31 days).
4 · Reply
accretivewealth
accretivewealth Aug. 18 at 5:09 PM
$NTLA stock acts like death, ugh!
0 · Reply
0x126
0x126 Aug. 18 at 3:01 PM
$NTLA no news? Price is just games
1 · Reply
SternInvesting10
SternInvesting10 Aug. 18 at 3:00 PM
$CRSP $NTLA Weak and pathetic Cathie Wood scams. She got it wrong but can’t admit it. So double down and lose your investors hundreds of millions in losses and billions in opportunity costs.
2 · Reply
fubotvfan
fubotvfan Aug. 18 at 2:47 PM
$NTLA back to $10, can't find a stock as weak as this
0 · Reply
chole1
chole1 Aug. 18 at 2:14 PM
$NTLA HOW F... LONG DOES IT TAKE THEM TO FINISH THE ROLLING BLA?!!
1 · Reply
THE_MADMAN
THE_MADMAN Aug. 18 at 11:11 AM
$NTLA back into this snake. Something has to give nothing for months.
0 · Reply
ImFullyTorqued
ImFullyTorqued Aug. 18 at 2:41 AM
$NTLA some intern at baker bros is flip flopping; sold entire stake end of 2025 at the bottom just to buy back in 6 months later at double the price… maybe I should work there
1 · Reply
SignoreRossi
SignoreRossi Aug. 17 at 7:22 PM
$CELH $FOUR $NTLA $TTD get help you 🤡
0 · Reply
Cheesyisi
Cheesyisi Aug. 17 at 5:16 PM
$NTLA
0 · Reply
Hopipaytrader
Hopipaytrader Aug. 17 at 4:21 PM
$NTLA nutella
0 · Reply
MrHurts
MrHurts Aug. 17 at 3:17 PM
$NTLA LET'S GO 🚀🚀🚀
0 · Reply
Shirzo
Shirzo Aug. 17 at 2:35 PM
$NTLA
0 · Reply
ChaseSnortin
ChaseSnortin Aug. 17 at 1:56 PM
$CELH $FOUR $NTLA $TTD long every uptick of Celsius!
1 · Reply
SternInvesting10
SternInvesting10 Aug. 17 at 1:55 PM
$FOUR short every single uptick of this dogshit $TTD short every single uptick of this dogshit $CELH short every single uptick of this dogshit $NTLA short every single uptick of this dogshit
2 · Reply
Probiotech
Probiotech Aug. 17 at 11:40 AM
$NTLA
0 · Reply